https://doi.org/10.4081/jbr.2026.14692
A randomized, double-blind pilot study of a multi-strain probiotic formulation on depressive symptoms in adults
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 29 April 2026
The gut–brain axis represents a bidirectional communication pathway influencing mood through microbiota-related mechanisms. This randomized, double-blind, active-controlled pilot trial evaluated the effects of a multi-strain Lactobacillus spp. probiotic formulation added to an active control on depressive symptoms in adults with mild-to-moderate depressive symptoms. Sixty participants were randomly assigned to receive either a daily combination containing L. rhamnosus HN001, L. rhamnosus SP1, L. acidophilus LA1, and L. reuteri LR92 (3×10⁹ CFU total) plus L-theanine and Eschscholtzia californica (probiotic group) or an identical active control containing L-theanine and E. californica alone for six weeks. Depressive symptoms were assessed using the Patient Health Questionnaire-9 (PHQ-9) and the Beck Depression Inventory-II at baseline, week 3, week 6, and after a three-week washout. Significant within-group reductions in depressive symptom scores were observed in the probiotic group, while changes in the active control group were smaller and not statistically significant. However, between-group comparisons did not reach statistical significance at any time point. These findings suggest that the probiotic-containing formulation was associated with improvements in depressive symptoms when administered on top of an active control. Due to the study design, effects cannot be attributed specifically to the probiotic component alone. Larger trials incorporating inert placebo controls and microbiome analyses are warranted.
Downloads
1. Kit A, Conway K, Makarowski S, et al. Can the gut-brain axis provide insight into psilocybin's therapeutic value in reducing stress? Neurobiol Stress 2025;36:100732.
2. Khan MT, Zohair M, Khan A, et al. From gut to brain: the roles of intestinal microbiota, immune system, and hormones in intestinal physiology and gut-brain-axis. Mol Cell Endocrinol 2025;112599.
3. Bankah AZ, Tagoe TA, Darko E, et al. Combined administration of Lactobacillus or Bifidobacterium offers enhanced antidepressant and anxiolytic activity in a dose dependent manner. Brain Behav 2025;15:e70564.
4. Mehta I, Juneja K, Nimmakayala T, et al. Gut microbiota and mental health: a comprehensive review of gut-brain interactions in mood disorders. Cureus 2025;17:e81447.
5. Rathore K, Shukla N, Naik S, et al. The bidirectional relationship between the gut microbiome and mental health: a comprehensive review. Cureus 2025;17:e80810.
6. Eastwood J, van Hemert S, Stolaki M, et al. Exploring the acute and chronic effects of a mul-tistrain probiotic supplement on cognitive function and mood in healthy older adults: a ran-domized controlled trial. Am J Clin Nutr 2025;121:1268-80.
7. Dacaya P, Sarapis K, Moschonis G. The role and mechanisms of probiotic supplementation on depressive symptoms: a narrative review. Curr Nutr Rep 2025;14:53.
8. Guan Y, Zhu R, Zhao W, et al. Effects of Lacticaseibacillus paracasei K56 on perceived stress among pregraduate students: a double-blind, randomized, placebo-controlled trial. Front Nutr 2025;12:1544713.
9. Mayer EA. Gut feelings: the emerging biology of gut-brain communication. Nat Rev Neurosci 2011;12:453-66.
10. Cryan JF, O'Riordan KJ, Cowan CSM, et al. The microbiota-gut-brain axis. Physiol Rev 2019;99:1877-2013.
11. Foster JA, Rinaman L, Cryan JF. Gut-brain axis: how the microbiome influences anxiety and depression. Nat Rev Neurosci 2017;18:374.
12. Strandwitz P. Neurotransmitter modulation by the gut microbiota. Brain Res 2018;1693:128-33.
13. Liu RT. The microbiome as a novel paradigm in studying stress and mental health. Am Psychol 2017;72:655.
14. Hidese S, Ogawa S, Ota M, et al. Effects of L-theanine administration on stress-related symptoms and cognitive functions in healthy adults: a randomized controlled trial. Nutrients 2019;11:2362.
15. Hidese S, Ota M, Wakabayashi C, et al. Effects of chronic L-theanine administration in patients with major depressive disorder: an open-label study. Acta Neuropsychiatr 2017;29:72-9.
16. Fedurco M, Gregorová J, Šebrlová K, et al. Modulatory effects of Eschscholzia californi-ca alkaloids on recombinant GABAA receptors. Biochem Res Int 2015;2015:617620.
17. Vogt NM, Kerby RL, Dill-McFarland KA, et al. The gut microbiota-brain axis in health and disease. Gastroenterol Clin North Am 2017;46:77-89.
18. Bonaz B, Bazin T, Pellissier S. The vagus nerve at the interface of the microbiota-gut-brain axis. Front Neurosci 2018;12:49.
19. Hill C, Guarner F, Reid G, et al. Expert consensus document: the International Scientific As-sociation for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 2014;11:506-14.
20. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001;16:606-13.
21. Cho HS, Choi JH, Park KH, et al. Standardization of the Korean version of Patient Health Questionnaire-9 as a screening instrument for major depressive disorder. Clin Psychopharmacol Neurosci 2021;19:104-11.
22. Beck A, Steer R, Brown G. Manual for Beck Depression Inventory II (BDI-II). San Antonio, TX: Psychology Corporation; 1996.
23. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007;39:175-91.
24. Shen F, Zhu H, Bao Z, et al. Lactiplantibacillus plantarum T34 alleviates constipation by en-hancing intestinal barrier and modulating gut homeostasis. Food Biosci 2025;66:106195.
25. Zhong H, Xu J, Yang M, et al. Protective effect of anthocyanins against neurodegenerative diseases through the microbial-intestinal-brain axis: a critical review. Nutrients 2023;15:496.
26. Verma A, Inslicht SS, Bhargava A. Gut-brain axis: role of microbiome, metabolomics, hor-mones, and stress in mental health disorders. Cells 2024;13:1436.
27. Steenbergen L, Sellaro R, van Hemert S, et al. A randomized controlled trial to test the effect of multispecies probiotics on cognitive reactivity to sad mood. Brain Behav Immun 2015;48:258-64.
28. Reis DJ, Ilardi SS, Punt SEW. The anxiolytic effect of probiotics: a systematic review and meta-analysis of the clinical and preclinical literature. PLoS One 2018;13(6):e0199041.
29. Li Y, Zhong X, Cheng G, et al. Probiotics for depression and anxiety: a systematic review and meta-analysis. J Affect Disord 2023;324:646-60.
30. Liu Y, Zhang W. Recent advances in understanding the gut-brain axis. Nat Rev Neurosci 2023;24:156-71.
31. Cryan JF, O'Riordan KJ. The gut microbiome in neurological disorders. Lancet Neurol 2020;19:179-94.
32. Valles-Colomer M, Falony G, Darzi Y, et al. The neuroactive potential of the human gut mi-crobiota in quality of life and depression. Nat Microbiol 2019;4:623-32.
33. Mayer EA, Tillisch K, Gupta A. Gut microbiota: a player in depression and anxiety. Nat Rev Gastroenterol Hepatol 2023;20:3-15.
CRediT authorship contribution
All authors contributed equally to the present article.
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.